SARM Review Tables

Study Title	ClinicalTrials.gov Identifier	Phase	Design	Intervention	Patient Population	Primary outcome	Status
Pembrolizumab and Enobosarm in Treating Patients with Androgen Receptor Positive Metastatic Triple Negative Breast Cancer	NCT02971761	Phase 2	Intervention model: single group assignment	Enobosarm + Pembrolizumab	Patients with metastatic triple negative breast cancer	Safety and tolerability of treatment, response rate	Recruiting; estimated primary completion June 2018
Study to Assess Enobosarm (GTx-024) in Postmenopausal women with Stress Urinary Incontinence (ASTRID)	NCT03241342	Phase 2	Randomized placebo controlled	Enobosarm vs placebo	Postmenopausal women aged 18–80 with stress urinary incontinence	Change in number of stress urinary incontinence episodes	Not yet recruiting
A Selective Androgen Receptor Modulator For Symptom Management in Prostate Cancer	NCT02499497	Phase 2	Randomized placebo controlled trial	LY2452473 vs placebo	Men who have undergone prostatectomy for prostate cancer	Harbor-UCLA 7-day Sexual Function Questionnaire	Recruiting; estimated primary completion March 2019
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK 2881078 and Study to Evaluate he Effect of CYP3A4 Inhibition on PK of GSK2881078	NCT02567773	Phase 1	Randomized placebo controlled trial	Part A: GSK2881078 Vs Placebo Part B: GSK2881078 + Itraconazole	Part A: Healthy men aged 50–75, postmenopausal women Part B: Healthy men aged 18–60	Measures of tolerability and AEs, pharmacokinetic and pharmacoynamic measurements	Completed
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses	NCT 02045940	Phase 1	Randomized placebo controlled crossover assignment	GSK2881078 vs placebo	Healthy males aged 18–50	Safety and tolerability, pharmacokinetics, pharmacodynamics	Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects	NCT01696604	Phase 1	Randomized placebo controlled crossover assignment	GSK2849466 vs placebo	Healthy males aged 18–50	Safety and tolerability, pharmacokinetics, pharmacodynamics	Completed
Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of PF – 06260414 in Healthy Western and Japanese Male Subjects	NCT02070939	Phase 1	Randomized placebo controlled	PF-06260414 vs placebo	Healthy males aged 21–50	Safety and tolerability, pharmacokinetics, pharmacodynamics	Completed
GLPG0492 Pharmacodynamics	NCT01538420	Phase 1	Randomized placebo controlled	GLPG0492 vs placebo	Healthy males aged 18–50, post-menopausal women aged 35–65	Safety and tolerability, pharmacokinetics, pharmacodynamics, effect on protein synthesis in muscle	Completed